



DFIN CASE STUDY

How we helped
a biotech
company increase
collaboration and
optimize SEC filing.

NEW ActiveDisclosureSM
by **DFIN**

 **REVOLUTION**
MEDICINES

CORPORATE SNAPSHOT

Revolution Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients.


Their innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches.



Large Accelerated Filer



As of December 5, 2022
— Market cap of
~\$2.16B



3 development-stage
candidates in clinical trials



Mission Statement
Translating frontier oncology
targets to outsmart cancer™

CHALLENGE

Boost collaboration to save time and drive efficiencies

With a variety of projects, Revolution Medicines was challenged when it came to real-time collaboration with their team and needed to find a way to simplify their financial reporting process.

Revolution Medicines was in search of a tool that allowed for team members to review documents simultaneously and review XBRL tagging. Since they did not have a way to collaborate in real-time, this led to hours of manual review, which was time-consuming.



SOLUTION

New ActiveDisclosure is Faster, Easier to Use, and More Affordable

Revolution Medicines was looking for a solution that would allow their team to collaborate in real-time and to increase efficiency of their financial reporting and SEC filing. New ActiveDisclosure allowed the team to easily collaborate on projects in real-time, simplify iXBRL tagging and streamline processes that were time-consuming in the past. New ActiveDisclosure also saved the client time and allowed their team to work in Excel and link data for collaboration and reporting.



SECURE COLLABORATION

Multiple contributors can simultaneously develop and review content



EXPERT SUPPORT

24/7/365 support made onboarding seamless



SAVES TIME

Intuitive tools for ease of use and speed to filing

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly, ↑

010-Cover

Josh Duncan Today - 11:16 AM

030-Balance Sheets

Stan Smith Today - 9:55 AM

040-Statements of Operations

Amy Flannery Today - 12:29 AM

Do you want to replace this workbook?

Original	Updated
11 Tables	11 Tables
105 Items	105 Items

Assets

Current Assets:

Cash

Accounts receivable

Prepaid expense

Total current assets

Building and land

“

New AD makes
SEC reporting and
filing a breeze!

KAUSHIK HANSJEE

Executive Director, Finance and Controller


ASHA INAMDAR

Senior Manager, SEC Reporting



Affordable and Collaborative with Greater Functionality

New ActiveDisclosure is purpose-built with advanced capabilities for fast, accurate reporting. By seamlessly integrating Excel and other data sources, clients that use our secure platform save time, reduce errors, and lower overall costs.



PURPOSE-BUILT

Core tools you need for successful SEC filing and financial reporting, without extra functionalities you'll never use



INTUITIVE

Easy-to-use software with no costly add-ons, hidden costs or annual upsells



EFFICIENT

Streamlines reporting with features like data linking, commenting, Intelligent iXBRL tagging, and more



CONNECTED

Simple integration to your current data sources and tech stack (e.g. Excel/MS Office, ERP)



EXPERT-DRIVEN

24/7/365 support by DFIN financial and SEC reporting experts dedicated to your success



SECURE

Best-in-class, built-in security tools ensure mitigation of data and risk



Get in touch

[DFINsolutions.com](https://www.dfin.com)

DFIN Global Headquarters
35 West Wacker Drive
Chicago, Illinois 60601
United States
+1 800 823 5304

APAC: +852 2522 3803
EMEA: +44 203 047 6100
LATAM: +55 11 3031 6327